0.420
-0.020
(-4.55%)
Delayed:
2:46PM EDT
OTCBB
data delayed by 15 mins -
Disclaimer
Currency in USD
| Range | 0.41 - 0.44 |
| 52 week | 0.28 - 0.89 |
| Open | 0.41 |
| Vol / Avg. | 257,320.00/1.07M |
| Mkt cap | 128.36M |
| P/E | - |
| Div/yield | - |
| EPS | -0.10 |
| Shares | 305.63M |
| Beta | 0.62 |
| Inst. own | 50% |
Events
Jul 31, 2013
Q2 2013 A.P. Pharma Inc. Earnings Release
Jun 12, 2013
A.P. Pharma Inc. Annual Shareholder Meeting
- 1:00PM EDT -
Mar 28, 2013
A.P. Pharma Inc. Corporate Update Conference Call -
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -60.13% | -64.79% |
| Return on average equity | -64.75% | -72.31% |
| Employees | 32 | - |
| Carbon Disclosure Rating | - | - |
Address
Website links
External links
Discussion Group - Google Finance
Advertisement
Description
A.P. Pharma, Inc. (A.P. Pharma) is a specialty pharmaceutical company developing pharmaceutical products using its Biochronomer polymer-based drug delivery platform. The Company�s lead product candidate, APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting (CINV) for patients undergoing both moderately and highly emetogenic chemotherapy and for the prevention of delayed CINV for patients undergoing moderately emetogenic chemotherapy. APF530 contains the 5-HT3 antagonist granisetron formulated in the Company�s Biochronomer drug delivery system, which allows therapeutic drug levels to be maintained for five days with a single subcutaneous injection.
Officers and directors
| Kevin C. Tang | Chairman of the Board | |
| Robert Rosen | President, Director | |
| Barry D. Quart Ph.D. | Chief Executive Officer, Director | |
| John B. Whelan MBA | Chief Financial Officer | |
| Stephen R. Davis | Chief Operating Officer, Executive Vice President, Director |